FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung Cancer with EGFR exon 20 Insertion Mutations By Ogkologos - July 25, 2025 215 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Oncomine Dx Express Test as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... May 8, 2024 From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Embedding research integrity at the core of our science July 28, 2021 Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 Load more HOT NEWS What to Know About Navigating Your Cancer Care During An Extreme... EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous... EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin
